Nuvectis Pharma Past Earnings Performance
Past criteria checks 0/6
Nuvectis Pharma's earnings have been declining at an average annual rate of -44.9%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-44.9%
Earnings growth rate
5.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -182.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Jan 06
Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Oct 03We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
Jan 31Nuvectis Pharma forms scientific advisory board for research and development of drugs
Sep 28Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04
Aug 05Nuvectis Pharma declines 13%, announces $15.9M private placement
Jul 27We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
May 04Revenue & Expenses BreakdownBeta
How Nuvectis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -22 | 8 | 14 |
| 30 Sep 23 | 0 | -22 | 7 | 14 |
| 30 Jun 23 | 0 | -22 | 7 | 14 |
| 31 Dec 22 | 0 | -19 | 6 | 12 |
| 30 Sep 22 | 0 | -15 | 5 | 3 |
| 30 Jun 22 | 0 | -13 | 4 | 3 |
| 31 Mar 22 | 0 | -16 | 4 | 4 |
| 31 Dec 21 | 0 | -13 | 3 | 2 |
Quality Earnings: NVCT is currently unprofitable.
Growing Profit Margin: NVCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NVCT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NVCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: NVCT has a negative Return on Equity (-182.44%), as it is currently unprofitable.